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Abstract
Background: AIB1 (amplified in breast cancer I) is a member of the p160 steroid receptor coactivator family. AIB1
is frequently overexpressed in breast cancer and has functions that promote oncogenesis that are independent of
estrogen receptor (ER) coactivation. We investigated prognostic significance of AIB1 and relationship between AIB1
and ER, progesterone receptor (PR), androgen receptor (AR), DAX-1, and HER2.
Methods: RNA in situ hybridization (ISH) and immunohistochemical (IHC) staining for AIB1, IHC staining for ER and
the progesterone receptor (PR) and IHC staining and silver in situ hybridization (SISH) for HER2 were performed for
185 breast cancer cases.
Results: A high level of expression of AIB1 mRNA was observed in 60.0% of tumors. IHC analysis detected AIB1
positivity in 47.3% of tumors, which did not correlate with AIB1 mRNA expression (p = 0.24, r = 0.10). AIB1 protein
expression correlated with AR and DAX-1 expression (p = 0.01, r = 0.22 and p = 0.02, r = 0.21, respectively) but not
with ER or PR expression (p = 0.14, r = -0.13 and p = 0.16, r = -0.12, respectively). AIB1 protein expression
correlated with the amplification of the HER2 gene (p = 0.03, r = 0.19). In contrast to AIB1 protein expression, AIB1
mRNA expression did not correlate with AR, DAX-1, ER, and PR expression, and the amplification of the HER2 gene
(p > 0.05 for all).
There were trends that strong AIB1 protein expression correlated with poorer disease free survival (p = 0.07).
Strong AIB1 protein expression correlated with poorer overall survival (p = 0.04). Among the ER-negative subgroup,
strong AIB1 protein expression correlated with poorer disease free survival and overall survival (p = 0.01 and p <
0.01, respectively).
Conclusions: Strong AIB1 protein expression was poor prognostic factor in breast cancer, especially in ER-negative
breast cancers. Further investigation is essential to determine whether AIB1 might be effective therapeutic targets
for ER-negative breast cancers.
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Background
Breast cancer is the most frequently diagnosed cancer
and the leading cause of cancer death among females,
accounting for 23% of all cancers [1]. Estrogen hor-
mones regulate the development and growth of normal
and malignant breast epithelial cells via the estrogen
receptor (ER). Selective estrogen receptor modulators
such as tamoxifen are well-established treatment modal-
ities for ER-positive breast cancer. However, a significant
proportion of ER-positive patients suffer from endocrine
therapy resistance. Furthermore, up to 30% of breast
cancers are negative for ER, lacking effective targeted
therapy [2].
Estrogen signaling are the interactions of ER with
transcriptional coactivators including p/CAF, CREB
binding protein(CBP), p300 and the p160 family mem-
bers [3]. AIB1 (amplified in breast cancer I) is a member
of the p160 steroid receptor coactivator family, which
includes SRC-1 and SRC-2 [4]. It is located on chromo-
some 20q12, a common region of amplication in breast
cancer. It is recruited to hormone-responsive genes
through their interaction with activated receptors and
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which in turn remodels chromatin through histone
modifications and facilitates RNA polymerases II tran-
scription [5]. AIB1 can activate nuclear receptors such
as ER and the androgen receptor (AR) and transcription
factors such as E2F1 [6]. Anzick et al. have demon-
strated that the AIB1 gene is overexpressed in breast
cancer and ovarian malignancy [5]. Other previous stu-
dies have indicated that AIB1 has important roles in
carcinogenesis in breast tissue and is associated with
resistance to endocrine treatment [5,7]. AR, which is
detected in ER-negative breast cancer, has recently been
suggested as a therapeutic target for a subset of triple-
negative breast cancers [8]. AIB1 is a preferred co-acti-
vator for AR in prostate cancer [9].
In this study, we investigated the prognostic signifi-
cance of AIB1 and its relationship with steroid hormone
receptors including ER, the progesterone receptor (PR),
and AR, DAX-1, and HER2.
Materials and methods
Patients and tissue samples
We analyzed 185 patients who underwent surgical resec-
tion and had confirmed breast carcinoma between Janu-
ary 2004 and December 2008 at the Kangnam St. Mary’s
Hospital at the Catholic University of Korea. The normal
tissue of breast, palatine tonsil, placenta and pancreas for
control were obtained after anonymization. This study
was approved by the hospital’s Institutional Review Board
a n df o l l o w e dr e c o m m e n d a t i o ns for tumor marker prog-
nostic studies [10]. The mean age at diagnosis was 51
years (range, 30-71 years). Most tumors (n = 173) were
invasive ductal carcinomas. The remaining tumors were
3 cases of invasive lobular carcinoma, 4 cases of muci-
nous carcinoma, 2 cases of medullary carcinoma, 1 tubu-
lar carcinoma and 2 invasive micropapillary carcinoma.
Data regarding patient demographics were obtained by
reviewing medical records. The immunohistochemical
( I H C )s t a i n i n gd a t af o rE R ,P R ,A R ,D A X - 1 ,a n dH E R 2
were obtained from a previous study in 133 overlapping
patients [11]. The median length of follow-up was 52.5
months (range, 4.2-89.8 months). Within the observation
period, there were 5 breast cancer-specific deaths and 22
breast cancer relapses. The other clinicopathologic char-
acteristics are summarized in Table 1.
Tissue microarray
To construct the tissue microarray block, 2 mm-sized core
biopsies were taken from morphologically representative
areas of formalin-fixed and paraffin-embedded tumor tis-
sue and were assembled on a recipient paraffin block con-
taining 30 biopsies using a precision instrument (Micro
Digital Co., Gunpo-si, Gyeonggi-do, Korea). After con-
struction, 4 μm sections were removed, and the histology
was verified by hematoxylin-eosin staining. Each of the
recipient blocks included one core of normal breast for
internal control, two cores of palatine tonsil and placenta
for proper TMA orientation and universal control.
mRNA in situ hybridization (ISH)
A commercially available mRNA ISH kit (QuantiGen-
e
®ViewRNA, Paranomics Inc., Fremont, CA, USA) was
Table 1 Correlation of clinicopathological parameters and
AIB1 mRNA expression in 185 breast cancer patients
AIB1 mRNA (n = 185)
low high p-value
Age
≤ 50 59 39
> 50 52 35 0.54
Histological type
IDC 107 66








T3 4 4 0.01
Lymph node metastasis
negative 59 46





T4 3 0 0.13
ER
negative 30 27
positive 81 47 0.12
PR
negative 31 27
positive 80 47 0.14
HER2
negative 85 53
positive 26 21 2.28
AR
negative 19 5
positive 67 38 0.11
DAX-1
negative 25 7
positive 61 36 0.08
AIB1: amplified in breast cancer I; IHC: immunohistochemistry; IDC: invasive
ductal carcinoma; ER: estrogen receptor; PR: progesterone receptor; and AR:
androgen receptor.
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micrometer sections for the paraffin embedded tissue
arrays were cut and attached to positively charged glass
slides. The samples were incubated with a pretreatment
solution followed by protease digestion. An AIB1-gene-
specific probe was designed (forward primer:
CTAATCCCTATGGCCAAGCA and reverse primer:
CTTTCGTCACTCTGGCCTTC). A probe set was hybri-
dized and amplifier molecules were hybridized to each
pair of oligonucleotides. The fast red substrate, alkaline
phophatase breaks down the substrate to form a precipi-
tate. AIB1 mRNA is visualized using confocal microscopy
(LSM 510 Meta, Carl Zeiss, Oberkochen, Germany).
AIB1 mRNA was independently examined by two pathol-
ogists. The expression level was semi-quantitatively
determined based on the number of cytoplasmic red dots
in the tumor cells (0, 1+, 2+, and 3+). In normal breast
tissue, the expression of AIB1 mRNA was 1+. For the
purpose of further analysis, the data were organized into
two categories using a cut-off value equal to the AIB1
mRNA level in normal breast: low expression (0 and 1+)
and high expression (2+ and 3+) (Figure 1).
Immunohistochemistry (IHC)
Four-micrometer sections of the formalin-fixed and par-
affin-embedded tissue arrays were deparaffinised and
rehydrated in a graded series of alcohol. Endogenous
peroxidase activity was inhibited using 3% hydrogen per-
oxide. Heat-induced epitope retrieval was conducted by
immersing the slides in Coplin jars that were filled with
0.01 M citrate buffer (pH6.0), boiling the slides in a
microwave vacuum histoprocessor (RHS-1, Milestone,
Bergamo, Italy) at a controlled final temperature of 121°
C for 15 min and cooling the slides to room tempera-
ture for 15 min. The tissue arrays were processed in an
automatic IHC staining machine (Lab Vision
h hG iG
kG jG lG
Figure 1 RNA in situ hybridization for AIB1 mRNA. A: Expression of AIB1 mRNA was 1+ in normal breast tissue samples. B: Breast cancer
tissue sample with 1+ AIB1 mRNA expression (×400). B: Breast cancer tissue sample with negative AIB1 mRNA expression (×400). C: Breast
cancer tissue sample with low (1+) AIB1 mRNA expression (×400). D: Breast cancer tissue sample with high (2+) AIB1 mRNA expression (×400). E:
Breast cancer tissue sample with high (3+) AIB1 mRNA expression (×400).
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DAKO ChemMate™ EnVision™ system (DAKO, Car-
pinteria, CA, USA) according to the manufacturer’s pro-
tocol. The following antibodies were used: AIB1 (1:100,
NCoA-3, Santa cruz biotechnology), ER (1:100, 6F11,
Novocastra, Newcastle, UK), PR (1:50, PgR636, DAKO),
and HER2 (1:200, polyclonal, DAKO). The immunoreac-
tions were visualized with 3-3’-diaminobenzidine (DAB)
and counterstained with Mayer’s hematoxylin. Positive
control for AIB1 was paraffin embedded pancreas tissue,
which showing cytoplasmic staining of exocrine glands
[12].
Immunostaining for AIB1, ER, PR and HER2 was
independently examined by two pathologists. The
tumors with > 10% nuclear-stained cells were consid-
e r e dp o s i t i v ef o rA I B 1 ,E R ,o rP R .F o rA I B 1 ,t h e i r
staining intensities were classified into three categories:
0 ,n e g a t i v e ;1 + ,w e a k l yp o s i t i v e ,a n d2 + ,s t r o n gp o s i t i v e
(Figure 2). For ER and PR (including previously stained
overlapping cases [11]), the proportion of positively
stained cells was classified into 5 categories: 0, negative;
1+, 11-25%; 2+, 26-50%; 3+, 51-75%; 4+, 76-100%. The
HER2 expression level was classified into four groups
according to the ASCO/CAP guideline recommenda-
tions for HER2 IHC [13].
HER2 silver in situ hybridization (SISH)
The HER2 status was confirmed using HER2 SISH,
when the IHC staining result for HER2 was equivocal (2
+). Four-micrometer sections of the tissue arrays were
stained according to the manufacturer’sp r o t o c o l sw i t h





Figure 2 Immunohistochemical staining for AIB1. A: Expression of AIB1 was negative in normal breast tissue samples (×200). B: Breast cancer
tissue sample with negative AIB1 staining (×200). C: Breast cancer tissue sample with weak AIB1 staining (×200). D: Breast cancer tissue sample
with strong AIB1 staining (×200).
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and optimally formulated for use with the ultraView
SISH Detection Kit and the Ventana BenchMark
®XT
automated slide stainer (Ventana). The black dot signals
for the HER2 gene were counted in at least 20 tumor
cells and classified into 3 categories: negative if HER2
signals/nucleus < 4, equivocal if HER2 signals/nucleus
4-6, and positive if HER2 signals/nucleus > 6.
Statistical analysis
All statistical analyses were performed using SPSS (ver-
sion 13.0, SPSS Inc., Chicago, IL, USA) for Windows.
The association between mRNA ISH and IHC results
and clinicopathological variables was evaluated using the
Chi-square test or Fisher’s exact probability test. The
association between AIB1 and steroid hormones and co-
factors was evaluated using the Spearman correlation
test. Kaplan-Meier plots were used to estimated recur-
rence free survival and overall survival, and the statisti-
cal significance was determined by the log-rank test. All
Kaplan-Meier curves were curtailed when less than five
individuals remained at risk. P values less than 0.05
were considered significant.
Results
AIB1 mRNA expression does not correlate with AIB1
protein expression
A total of 6 (3.2%), 105 (56.8%), 50 (27.0%) and 24
(13.0%) tumors had 0, 1+, 2+, and 3+ of AIB1 mRNA,
respectively (Figure 1). Using a cut-off value equal to
the AIB1 mRNA in normal breast tissues (1+), we deter-
mined that 60.0% of tumors had low levels (0 and 1+) of
AIB1 mRNA expression and 40.0% of tumors had high
levels (2+ and 3+). Palatine tonsil and placenta showed
high expression (3+) and low expression (0) of AIB1
mRNA, respectively. Using IHC analysis, we detected
AIB1 positivity in 47.3% (61 out of 129) of tumors,
including 46 weakly positive and 15 strongly positive
cases (Figure 2). Normal breast was not stained, and
palatine tonsil and placenta were weakly positive and
negative, respectively. AIB1 mRNA expression did not
correlate with the IHC result for AIB1 (p = 0.24, r =
0.10). High expression of AIB1 mRNA correlated with a
larger tumor size (p = 0.01) (Table 1).
AIB1 protein expression correlates with AR, DAX-1, and
HER2 expression
Using a cut-off value as previously described [11], the
positive rates for ER, PR, AR, and DAX-1 were 69.2%,
68.6%, 81.4% and 75.2%, respectively. AIB1 protein
expression correlated with histologic type (p = 0.04)
(Table 2). HER2 was amplified in 25.4% of tumors (47
out of 185). AIB1 protein expression correlated with AR
and DAX-1 expression (p = 0.01, r = 0.22 and p = 0.02,
r = 0.21, respectively) but not with ER or PR expression
(p = 0.14, r = -0.13 and p = 0.16, r = -0.12, respectively)
(Table 3). AIB1 protein expression correlated with the
amplification of the HER2 gene (p = 0.03, r = 0.19)
(Table 3). In contrast to AIB1 protein expression, AIB1
mRNA expression did not correlated with AR, DAX-1,
ER, and PR expression, and the amplification of the
HER2 gene (p > 0.05, each).
Table 2 Correlation of clinicopathological parameters and
AIB1 protein expression in 129 breast cancer patients
AIB1 protein (n = 129)
negative positive p-value
Age
≤ 50 36 34
> 50 32 27 0.44
Histological type
IDC 63 61








T3 2 1 0.84
Lymph node metastasis
negative 41 33





T4 1 2 0.13
ER
negative 18 21
positive 50 40 0.22
PR
negative 18 23
positive 50 38 0.12
HER2
negative 55 39
positive 13 22 0.02
AR
negative 17 7
positive 51 54 0.03
DAX-1
negative 23 9
positive 45 52 0.01
AIB1: amplified in breast cancer I; IHC: immunohistochemistry; IDC: invasive
ductal carcinoma; ER: estrogen receptor; PR: progesterone receptor; and AR:
androgen receptor.
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factor in breast cancers
Disease-free survival lengths and overall survival lengths
according to the AIB1 mRNA levels were not signifi-
cantly different (p = 0.35 and p = 0.49, respectively)
(Figure 3A). There were trends that strong AIB1 protein
expression correlated with poorer disease free survival
(p = 0.07) (Figure 3B). Strong AIB1 protein expression
correlated with poorer overall survival (p = 0.04). In the
ER-negative subgroup, strong AIB1 protein expression
correlated with poorer diseasef r e es u r v i v a la n do v e r a l l
s u r v i v a l( p=0 . 0 1a n dp=<0 . 0 1 ,r e s p e c t i v e l y )( F i g u r e
3C). For the HER2-amplified subgroup, strong AIB1
protein expression did not have a significant impact on
patient survival time (P > 0.05), although mean survival
time was reduced (Figure 3D).
Discussion
AIB1 is a well-known transcriptional coactivator that
promotes the transcriptional activity of multiple nuclear
receptors such as ER, PR, the thyroid hormone receptor
and the retinoic acid receptor [5,14,15] AIB1 has also
been shown to coactivate other hormone receptor-inde-
pendent transcription factors such as STAT and AP-1
via histone acetylation/methylation [16]. Previous
reports have indicated that AIB1 regulates other signal-
ing pathways such as the PI3K/Akt/mTOR pathway
[17]. AIB1 transgenic mice (overexpressing AIB1 in
mammary glands) with ovariectomy, display a high inci-
dence of mammary tumors (48%, 48/100), and AIB1 has
functions that promote oncogenesis that are indepen-
dent of ER coactivation [17]. Therefore, further investi-
gation is required to ascertain the oncogenic role of
AIB1 in breast cancer independent of ER coactivation.
AIB1 gene (20q13) amplication occurred in 2-10% of
breast cancer smaples with high AIB1 mRNA expres-
sion. However, increased AIB1 mRNA levels have been
reported in 31-64% of breast cancer [18,19], suggesting
that another mechanism mediates AIB1 overexpression
Table 3 Association analyses of IHC results of AIB1, ER,
PR, AR, and DAX-1, and the HER2 gene status
AIB1 ER PR AR
ER -0.13/0.14 - 0.51/< 0.01 0.38/< 0.01
PR -0.12/0.16 0.51/< 0.01 - 0.31/< 0.01
AR 0.22/0.01 0.38/< 0.01 0.31/< 0.01 -
DAX-1 0.21/0.02 0.31/< 0.01 0.26/< 0.01 0.50/< 0.01
HER2 0.19/0.03 -0.33/< 0.01 -0.34/< 0.01 -0.16/0.08
The ratios represent r-value/p-value. AIB1: amplified in breast cancer I; ER:


















C.                                                                                                                                                     D.  
Figure 3 Kaplan-Meier survival curves to evaluate differences in disease-free survival.A :D F Sa c c o r d i n gt ot h eA I B 1m R N Ae x p r e s s i o n
level. B: DFS according to the AIB1 protein expression level. C: DFS according to the AIB1 protein expression level in ER-negative breast cancers.
D: DFS according to AIB1 protein expression in HER2 positive breast cancers.
Lee et al. World Journal of Surgical Oncology 2011, 9:139
http://www.wjso.com/content/9/1/139
Page 6 of 8independent of amplification. In our study, 40.0% of
tumors exhibited high expression of AIB1 mRNA and
47.3% of tumors exhibited positive AIB1 staining by
IHC analysis. Previous studies have reported that AIB1
protein and mRNA levels correlate well [7]. However,
our results do not confirm those reports. We showed
that the AIB1 mRNA level did not correlated with AIB1
protein level, which was detected using IHC analysis (p
= 0.24, r = 0.10). AIB1 protein levels are affected by var-
ious factors including the levels of AIB1 mRNA expres-
sion and stability; the translational activity, which may
be regulated by exogenous substances such as tamoxifen
and endogenous microRNAs such as mir-17-5p; and
proteasomal degradation [7,20-22].
AIB1 is an important oncogene in breast tissue and is
associated with poorer disease-free survival [23,24]. AIB1,
like the ER itself, is phosphorylated and thereby fuctionally
activated by MAPKs. Therefore high levels of activated
AIB1 could reduce the antagonist effects of tamoxifen [3].
Clinical studies by Osborne et al. [25] and Alkner et al. [26]
also reported that high AIB1 was associated with tamoxifen
resistance. In the same context, it could be partly explained
by resistance to antiestrogen therapy that strong AIB1 pro-
tein expression was correlated with poorer overall survival.
However, there seems to be another mechanism involved
other than resistance to antiestrogen therapy, because in
the ER-negative subgroup which did not get antiestrogen
therpy, strong AIB1 protein expression also correlated with
short disease-free and overall survival (p = 0.006 and p =
0.001, respectively). Harigopal et al. have reported that
AIB1 in ER-negative breast cancer is associated with a
negative prognostic effect [24]. In prostate cancer, Zou et
al. demonstrated the effect of AIB1 and AR depletion by
adenovirus vector-mediated siRNA expression on cell pro-
liferation [27]. Reduction of AIB1 and AR level results in
inhibition of androgen dependent and androgen-indepen-
dent tumor cell proliferation through direct control of cell
cycle genes, suggesting that AIB1 and AR may play impor-
tant roles in androgen ablation resistance by controlling
cell cycle gene expression [27]. Although many breast can-
cers express AR, the association of AR and AIB1 in breast
cancer has not been studied well. AIB1 binds specifically to
A Rv i at h ef i r s ta n dt h i r dL X X L Lm o t i f si nA I B 1a n dt oE R
via the second LXXLL motif in AIB1 [9]. Interestingly,
phosphorylation is required for AIB1 activity. AIB1 is selec-
tively phosphorylated when cells are treated with androgen
and estrogen [28].
DAX-1 functions as a global negative regulator of ster-
oid hormone production. However, the expression of
DAX-1 is positively correlated with the expression of
AR in breast cancer [29]. We previously reported that
DAX-1 is positively correlated with AR. In our previous
report, we suggested that DAX-1 might be a more effec-
tive target than AR in triple-negative breast cancer
because the overall expression rate of DAX-1 is high,
even in these triple-negative breast cancers [11]. In the
present study, AIB1 protein expression correlated with
the expression of the nuclear receptor AR and DAX-1.
Furthermore, positive IHC staining for AIB1 was
observed in 53.8% of ER-negative breast cancers. These
findings support the hypothesis that AR, DAX-1, and
AIB1 might be effective therapeutic targets, especially
for ER-negative cancers.
In the HER2-amplified subgroup, patients with strong
A I B 1p r o t e i ne x p r e s s i o ns h o wed reduced disease-free
survival according to the Kaplan-Meier plot (not statisti-
cally significant). Spears et al. have demonstrated tumors
that overexpress both HER2 and AIB1 have poorer
prognosis than HER2 and AIB1 only overexpressing
tumors [30].
Conclusions
Strong AIB1 protein expression was correlated with
poorer overall survival in ER-negative breast cancers.
Further investigation is essential to determine whether
AIB1 might be effective therapeutic targets for ER-
negative breast cancers, since positive IHC staining for
AIB1 was observed in 53.8% of ER-negative breast
cancers.
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